Is Serrapeptase compatible with breastfeeding? Do we have alternatives for Serrapeptase?

Serrapeptase

August 6, 2017 (Low Risk)

A proteolytic enzyme produced by Serratia spp. It consists of a chain of 470 amino acids of an average molecular weight of 50,600 daltons (Nakahama 1986).

It is administered orally to treat inflammation, edema, pain and, as a dietary supplement, to prevent cardiovascular disease.

There is no scientific evidence of its efficacy as an analgesic or as a health supplement and there is no data on its long-term safety (Bhagat 2013).

Due to its protein nature it would be digested and inactivated in the gastrointestinal tract, not being absorbed as such but in the form of loose amino acids, which is why its oral bioavailability is practically zero.

Since the last update we have not found any published data on its excretion in breast milk.

Its pharmacokinetic data (very high molecular weight and poor oral bioavailability) make it very unlikely that significant quantities will pass into breast milk.

It has been administered orally to treat breast engorgement or inflammation due to milk stasis (Kee 1989), but evidence for its effectiveness is insufficient and comes only from a study by Kee dating from 1989 which had poor results and came from few patients (Mangesi 2016, ABM 2016 y 2009).

Alternatives

Very Low Risk

Compatible. Not risky for breastfeeding or infant.

Low Risk

Moderately safe. Mild risk possible. Follow up recommended. Read the Comment.

High Risk

Poorly safe. Evaluate carefully. Use a safer alternative. Read the Comment.

Very High Risk

Not recommended. Cessation of breastfeeding or alternative.

Synonyms

  • Serrapeptidase
  • Serratia Proteinase
  • Serratiopeptidase

Writings

  • セラペプターゼ (Japanese)

References

  1. Mangesi L, Zakarija-Grkovic I. Treatments for breast engorgement during lactation. Cochrane Database Syst Rev. 2016Abstract
  2. Berens P, Brodribb W. ABM Clinical Protocol #20: Engorgement, Revised 2016. Breastfeed Med. 2016Abstract Full text (link to original source) Full text (in our servers)
  3. Academy of Breastfeeding Medicine. Protocolo Clínico de la ABM #20, revisión 2016: Congestión Mamaria. Breastfeed Medicine. 2016Abstract Full text (link to original source) Full text (in our servers)
  4. Bhagat S, Agarwal M, Roy V. Serratiopeptidase: a systematic review of the existing evidence. Int J Surg. 2013Abstract Full text (link to original source) Full text (in our servers)
  5. Kee WH, Tan SL, Lee V, Salmon YM. The treatment of breast engorgement with Serrapeptase (Danzen): a randomised double-blind controlled trial. Singapore Med J. 1989Abstract
  6. Nakahama K, Yoshimura K, Marumoto R, Kikuchi M, Lee IS, Hase T, Matsubara H. Cloning and sequencing of Serratia protease gene. Nucleic Acids Res. 1986Abstract Full text (link to original source) Full text (in our servers)